

Committee: Health and Wellbeing Board

Date: 25 March 2014

Agenda item:

Wards:

Subject: Pharmaceutical Needs Assessment

Lead officer: Dr Kay Eilbert, Director of Public Health

Lead member: Councillor Linda Kirby, Cabinet Member for Adult Social Care and Health

Forward Plan reference number:

Contact officer: Barry Causer, Public Health Commissioning Manager.

Recommendations:

That the Health and Wellbeing Board:

- A. Notes it has new statutory duties relating to the Pharmaceutical Needs Assessment (PNA).
 - B. Notes that following a competitive procurement exercise, joint with Sutton Council, that Primary Care Commissioning (PCC) has been appointed to produce Merton's PNA.
 - C. Notes that the PNA process will take up to 12 months, which includes a duty to consult with a number of interested parties for a minimum of 60 days.
 - D. Agrees to receive regular updates on progress of the PNA.
-

1. Purpose of report and executive summary

To update the Health and Wellbeing Board of progress on the development of the new Pharmaceutical Needs Assessment.

2. DETAILS

Background

- 2.1. As previously reported in July 2013, The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 includes a requirement that the Health and Wellbeing Board publish a Pharmaceutical Needs Assessment (PNA) by 1st April 2015.
- 2.2. A PNA is a tool for identifying current and future needs at a local level to explore the potential and improve quality and effectiveness of pharmaceutical services. It uses robust, up to date evidence to ensure that pharmacy services are provided in the right place and that public health services commissioned by local authorities meet the needs of the community that it serves.
- 2.3. It is used by NHS England when making decisions on applications to open new pharmacies and dispensing appliance contractor premises. Such decisions are appealable and decisions made on appeal can be challenged through the courts.

- 2.4. In advance of new PNAs being produced by the Health and Wellbeing Board, NHS England will use the existing PNA that NHS Sutton and Merton developed in 2010/2011 to inform its decision making on any applications made to open new premises.
- 2.5. This inherited PNA has been reviewed by the Department of Health to assess the extent to which the existing PNA produced by NHS Sutton and Merton meets the regulations. This review has shown that of the 40 required criteria,
- 10 are green and meet the criteria
 - 11 are yellow and partially meet the criteria
 - 10 are red and do not meet the criteria
 - 9 were not applicable and were not assessed.

This review has been produced to support discussions by the HWB to take ownership of their PNA and in determining what steps, if any, need to be taken to ensure that it meets its obligations under the regulations.

Health and Wellbeing Boards Statutory Duty

- 2.6. The HWB has a requirement to keep the PNA under review and publish a revised assessment within 3 years, keep the map up to date and make a revised assessment as soon as reasonably practicable where a significant changes to pharmaceutical need are identified.
- 2.7. To benefit from economies of scale a joint procurement exercise was undertaken with Sutton Council to appoint an organisation to deliver Merton's PNA. This exercise has now been completed and Primary Care Commissioning (PCC) has been appointed with a fixed price contract of £65,000. Merton is liable for 50% of the contract (available from the Public Health grant) and we estimate that this has saved in the region of £5,000 per borough.
- 2.8. The PNA process will be led by a steering group including representatives from Merton Council Public Health, Sutton Council Public Health NHS England, Merton CCG, Sutton CCG and The Merton Sutton and Wandsworth Local Pharmaceutical Committee.
- 2.9. The deadline for the HWB to publish a revised assessment is 1st April 2015; however we estimate that the process will take around 12 months with a final PNA ready for formal sign off at the HWB on the 25th November 2014.

3. ALTERNATIVE OPTIONS

None for the purpose of this report.

4. CONSULTATION UNDERTAKEN OR PROPOSED

None for the purpose of this report.

5. TIMETABLE

As set out in the report.

6. FINANCIAL, RESOURCE AND PROPERTY IMPLICATIONS

The financial implications as detailed in the report will be paid from the Public Health Grant.

7. LEGAL AND STATUTORY IMPLICATIONS

It is a statutory duty of the Health and Wellbeing Board to produce a Pharmaceutical Needs Assessment from April 2015.

8. HUMAN RIGHTS, EQUALITIES AND COMMUNITY COHESION IMPLICATIONS

None for the purpose of this report.

9. CRIME AND DISORDER IMPLICATIONS

None for the purpose of this report.

10. RISK MANAGEMENT AND HEALTH AND SAFETY IMPLICATIONS

None for the purpose of this report.

11. APPENDICES – THE FOLLOWING DOCUMENTS ARE TO BE PUBLISHED WITH THIS REPORT AND FORM PART OF THE REPORT

None

12. BACKGROUND PAPERS

None for the purpose of this report.

This page is intentionally left blank